Figure 3.

RelB reduction suppresses EEC cell growth in vivo. (a) RelB protein levels in HEC-1A and RL95-2 cells with shCon, shRelB-1 or shRelB-2. (b) Image of subcutaneous injection with HEC-1A and RL95-2 cells expressing shCon, shRelB-1 or shRelB-2. (c) Tumor growth in mice injected with HEC-1A (left) and RL95-2 cells stably expressing shCon, shRelB-1 or shRelB-2 (n=6 for each group). (d and e) Tumor volume in mice injected with HEC-1A (d) and RL95-2 (e) cells stably expressing shCon, shRelB-1 or shRelB-2 (n=6 for each group). (f and g) Tumor weight in mice injected with HEC-1A (f) and RL95-2 (g) cells stably expressing shCon, shRelB-1 or shRelB-2 (n=6 for each group). All data are presented as the mean±S.E.M., *P<0.05, **P<0.01, ***P<0.001